Coronary disease & ACS

OCT-Guided vs Angiography-Guided Coronary Stent Implantation in Complex Lesions: An ILUMIEN IV Substudy

J Am Coll CardiolPublished Secondary analysis of the ILUMIEN IV randomised trial

Authors' conclusion

In complex angiographic lesions, OCT-guided PCI led to a larger MSA and reduced the serious MACE, the composite of cardiac death, target-vessel MI, or stent thrombosis, compared with angiography-guided PCI at 2 years, but did not significantly improve TVF.

Study context

Population
Patients with complex angiographic lesions (long/multiple lesions with intended stent length ≥28 mm, bifurcation with intended 2-stent strategy, severe calcification, chronic total occlusion or in-stent restenosis)trial N = 2,487
Participants
992 vs 981
Comparison
Optical coherence tomography (OCT)-guided vs angiography-guided postpercutaneous coronary intervention (PCI)
  • OCT-guidedn = 992
  • Angiography-guidedn = 981reference
Primary endpoint
Final minimal stent area (MSA); serious MACE (cardiac death, target-vessel MI or stent thrombosis); TVF (cardiac death, target-vessel MI or ischemia-driven target-vessel revascularization)
Follow-up
2 years (MACE, TVF)
Methodological detailsmulticentre, subgroup analysis (complex angiographic lesions)
  • Multicentre
  • Subgroup analysis (complex angiographic lesions)

Primary result

As reported in the abstract

OCT-guided vs Angiography-guidedDifference, mm2 (95% CI)P value
Final MSA
0.30(0.14–0.47)
P < 0.001
OCT-guided vs Angiography-guidedHazard ratio (95% CI)P value
Serious MACE, 2 years
0.63(0.40–0.99)
P = 0.04
Target-vessel failure (TVF) not significantly different between groups (7.3% vs 8.8%; HR 0.82; 95% CI 0.59-1.12)
P = 0.20

Original publication

OCT-Guided vs Angiography-Guided Coronary Stent Implantation in Complex Lesions: An ILUMIEN IV Substudy. J Am Coll Cardiol. Published 15 May 2024. doi:10.1016/j.jacc.2024.04.037

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.